Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therap... by Rawstron, A, Kennedy, B, Evans, P, Davies, F, Richards, S, Haynes, A, Russell, N, Hale, G, Morgan, G, Jack, A, Hillmen, P

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. by Hale, G, Rebello, P, Brettman, L, Fegan, C, Kennedy, B, Kimby, E, Leach, M, Lundin, J, Mellstedt, H, Moreton, P, Rawstron, A, Waldmann, H, Osterborg, A, Hillmen, P

Results of the randomised phase II NCRI arctic (attenuated dose rituximab with chemotherapy in CLL) trial of low dose rituximab in previously untreated CLL by Munir, T, Cohen, D, Milligan, D, Schuh, A, McParland, L, Chalmers, A, Varghese, A, Rawstron, A, Allsup, D, Marshall, S, Smith, A, Collett, C, Gregory, W, Duncombe, A, Hillmen, P

Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the... by Pettitt, A, Jackson, R, Carruthers, S, Dodd, J, Dodd, S, Oates, M, Johnson, G, Schuh, A, Matutes, E, Dearden, C, Catovsky, D, Radford, J, Bloor, A, Follows, G, Devereux, S, Kruger, A, Blundell, J, Agrawal, S, Allsup, D, Proctor, S, Heartin, E, Oscier, D, Hamblin, T, Rawstron, A, Hillmen, P